Riociguat in transthyretin cardiac amyloidosis-data from a named patient use program in austria

Back

ESC Premium Access

Riociguat in transthyretin cardiac amyloidosis-data from a named patient use program in austria

Session: Cardiovascular drug therapy in special populations

Topic: Cardiovascular Pharmacotherapy, Other

Speaker: Doctor F. Duca (Vienna, AT)

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Doctor Franz Duca

Medical University of Vienna, Vienna (Austria)

2 presentations

0 follower

7 more presentations in this session

The monocentric, double-blind, placebo-controlled research of sildenafil impact in pediatric patients with secondary pulmonary hypertension.

Speaker: Associate Professor I. Palii (Chisinau, MD)

Obesity paradox outcomes after acute myocardial infarction in Japanese is due to optimal medical therapy in overweight patients

Speaker: Assistant Professor K. Sakamoto (Kumamoto, JP)

Elucidating the underlying mechanisms for the differential response to sodium channel blocker antiarrhythmic drugs in obese patients with atrial fibrillation

Speaker: Assistant Professor M. Mccauley (Chicago, US)

The impact of additional mineralocorticoid receptor antagonist on guideline-recommended medical therapy in acute heart failure patients with ischemic heart disease.

Speaker: Doctor T. Abe (Kawagoe, JP)

Polymorphism RS776746 in the gene of CYP3A5 as a possible predictor of clinical efficiency of bisoprolol in patients transplanted with acute coronary syndrome

Speaker: Doctor V. Shumkov (Saint Petersburg, RU)

Access the full session

Cardiovascular drug therapy in special populations

Speakers: Doctor F. Duca, Associate Professor I. Palii, Assistant Professor K. Sakamoto, Assistant Professor M. Mccauley, Doctor T. Abe...

Access

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources